Prostate Carcinoma Clinical Trial
Official title:
A Combination Therapy to Treat Cancer-Related Fatigue - NCI R01
This phase II/III trial studies how well methylphenidate and exercise work in reducing cancer-related fatigue in patients with prostate cancer. Methylphenidate is a type of central nervous system stimulant that can improve cognitive ability, mainly in memory and cognitive function. Exercise can improve mood and the physical aspects of cancer-related fatigue. Giving methylphenidate in combination with exercise may work better in reducing cancer-related fatigue in patients with prostate cancer.
PRIMARY OBJECTIVE: I. To determine if the combination of exercise (EX) plus methylphenidate (MP) is superior to exercise plus placebo in the treatment of cancer-related fatigue (CRF) in patients with prostate cancer scheduled to receive radiotherapy with androgen deprivation therapy for 12 weeks. SECONDARY OBJECTIVE: I. To determine the effects of combined exercise plus methylphenidate on quality-of-life, mood, physical, and cognitive measures. EXPLORATORY OBJECTIVES: I. To identify potential synergistic effects of exercise and methylphenidate in improvement of CRF. II. To explore changes in brain activity by electroencephalography (EEG) in responders (with 4 point or greater change in Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-F] scores) versus (vs) non-responders to the intervention. OUTLINE: Patients are randomized to 1 of 4 groups. GROUP I: Patients receive methylphenidate orally (PO) twice daily (BID) and undergo exercise program consisting of resistance training twice weekly (BIW) and walking 15- 40 minutes a day 4 days a week for 12 weeks. GROUP II: Patients receive a placebo PO BID and undergo exercise program consisting of resistance training BIW and walking 15-40 minutes a day for 4 days a week for 12 weeks. GROUP III: Patients receive methylphenidate PO BID and undergo stretching for 4 days a week for 12 weeks. GROUP IV: Patients receive a placebo PO BID and undergo stretching for 4 days a week for 12 weeks. After completion of study treatment, patients are followed up at 3 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04457232 -
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
|
Phase 1 | |
| Active, not recruiting |
NCT03661437 -
Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy
|
Early Phase 1 | |
| Completed |
NCT02337465 -
KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer
|
N/A | |
| Completed |
NCT03013413 -
Ultrasound-Based Imaging Using the Aixplorer System in Diagnosing Prostate Cancer in Patients Undergoing Biopsy
|
N/A | |
| Recruiting |
NCT06037863 -
Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial
|
N/A | |
| Active, not recruiting |
NCT03580499 -
Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy
|
N/A | |
| Completed |
NCT03326440 -
Virtual Environment Radiotherapy to Improve Patients' Compliance to Radiotherapy (RT) in Prostate Cancer
|
N/A | |
| Recruiting |
NCT04597359 -
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
|
Phase 2 | |
| Active, not recruiting |
NCT03263650 -
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
|
Phase 2 | |
| Active, not recruiting |
NCT04600336 -
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04299620 -
Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy
|
N/A | |
| Completed |
NCT04976257 -
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
|
Early Phase 1 | |
| Completed |
NCT02957981 -
The Genetic Education for Men Trial: Web-Based Education vs. Standard Care
|
N/A | |
| Withdrawn |
NCT03408561 -
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
|
N/A | |
| Enrolling by invitation |
NCT06347809 -
DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
|
||
| Enrolling by invitation |
NCT04254133 -
Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study
|
||
| Recruiting |
NCT05519878 -
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
|
N/A | |
| Recruiting |
NCT02994758 -
Development of Diagnostics and Treatment of Urological Cancers
|
N/A | |
| Completed |
NCT01497431 -
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT00002540 -
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)
|
N/A |